

InVivoMAb anti-mouse/human HER2 (domain III) (CD340)

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at <https://bioxcell.com/terms-and-conditions>.

Lot Specific Information

Lot Number: Lot Specific*
Volume: Lot Specific*
Concentration: Lot Specific* (generally 4 to 11 mg/ml) *
Total Protein: Lot Specific*

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number: BE0461
Clone: H2Mab-19
Isotype: Mouse IgG2b, κ
Recommended Isotype Control(s): InVivoMAb mouse IgG2b isotype control, unknown specificity
Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer
Immunogen: Recombinant human HER2 extracellular domain
Reported Applications: *in vivo* antitumor activity in HER2+ xenograft model
in vitro induction of ADCC in HER2+ cells
in vitro induction of CDC in HER2+ cells
Immunohistochemistry (frozen)
Flow cytometry
Formulation: PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin: <2EU/mg (<0.002EU/ μ g)
Determined by LAL gel clotting assay
Purity: >95%
Determined by SDS-PAGE
Sterility: 0.2 μ m filtered
Production: Purified from cell culture supernatant in an animal-free facility
Purification: Protein A
RRID:
Molecular Weight: 150 kDa

Description

The H2Mab-19 monoclonal antibody reacts with domain III of mouse and human receptor tyrosine-protein kinase erbB-2 (ERBB2), also known as human epidermal growth factor receptor 2 (HER2), CD340, or NEU. HER2 is a 185 kDa transmembrane receptor tyrosine kinase that is part of the EGFR family. The HER2 receptor contains a cytoplasmic tyrosine kinase domain, multiple cytoplasmic tyrosine residues that function as phosphorylation sites, a hydrophobic single-pass transmembrane domain, and an extensive extracellular domain (ECD) subdivided into four functional domains (I, II, III, and IV). Domains I and III facilitate ligand binding, domain II reinforces protein-protein interactions during dimerization, and domain IV stabilizes interactions between HER2 and its dimerization partner. HER2 lacks identified ligands; nonetheless, its homodimerization (HER2/HER2) and heterodimerization (EGFR/HER2, HER2/HER3, and HER2/HER4) facilitate HER2 activation, subsequently modulating downstream signaling pathways, including PI3K/Akt/mTOR and NF- κ B. HER2 is essential for cell proliferation, survival, and differentiation, and in cancers, dysregulated HER2 signaling or its overexpression often correlates with aggressive tumor growth. In addition to breast cancer, HER2 is overexpressed in gastric, gastroesophageal, colorectal, lung, endometrial, and ovarian cancers. The H2Mab-19 antibody has been shown to have anti-tumor activity in HER2+ xenograft models.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**

It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at <https://bioxcell.com/faqs>.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bioxcell.com/be0461?bxcs=9k1b3a#tab_references or scan the QR code below.



Bio X Cell, LLC

<https://bioxcell.com>

+1-866-787-3444

customerservice@bioxcell.com

Conditions: For research use only. Not for use in diagnostic or therapeutic procedures.

Not for resale.

Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2025 Bio X Cell, LLC